WASHINGTON - The number of patients in the U.S. awaiting organ transplantation outpaces the amount of transplants performed in the U.S., and many donated organs are not transplanted each year due to several factors, such as poor organ function, says a new report from the National Academies of Sciences, Engineering, and Medicine. Increasing the quality and quantity of organs that can be recovered from deceased donors and successfully transplanted requires organ donor intervention research, which is conducted on donated organs prior to their transplantation.
This research tests and assesses clinical interventions -- for example, medications, devices, and donor management protocols -- aimed at maintaining or improving the quality of donated organs prior to, during, and following transplantation. Transplantation research previously has focused almost exclusively on recipients and post-transplant health outcomes.
Organ transplantation is the optimal treatment for many end-stage organ-specific diseases. In 2016, more than 27,000 organs were transplanted from nearly 10,000 deceased individuals, yet nearly 5,000 donor organs were not transplanted. Many factors affect the supply of organs such as willingness to donate one's organs or those of a family member upon death, inability to allocate an organ within the short time frame during which it is viable for transplantation, or organs being found unsuitable for transplantation due to the health of the deceased donor, cause of death, or functional or anatomical abnormalities in the donor or donated organ. As of July 2017, more than 117,000 transplant candidates were awaiting an organ, 80 percent of which were kidneys.
"The very brief time frame in which donor intervention research must be conducted to maintain organ viability and ensure successful transport to the recipient, coupled with the fact that organs from a single donor may go to multiple recipients in different transplant centers throughout the United States, adds to the complexities of this research," said James Childress, John Allen Hollingsworth Professor of Ethics Emeritus at University of Virginia, and chair of the committee that conducted the study and wrote the report. "This report seeks to enable organ donor intervention research to move forward in a manner that ensures dignity and respect for deceased organ donors and their families and is within appropriate ethical, legal, and regulatory limits to save more lives, to improve the quality of lives, and to fully honor the gifts of organs for both current and future transplant recipients."
In order to improve coordination and sharing of information about donor preferences, all active U.S. donor registries should coordinate in order to create a single, unified, secure national donor registry that is easily accessible to organ procurement organizations (OPOs), the report says. All donor registry information collected by departments of motor vehicles should automatically feed into this single national registry.
To clarify legal guidance for authorization of organ donor intervention research, the committee recommended that the Organ Procurement and Transplantation Network (OPTN) and transplant community engage in public consultation and determine whether to revise the Uniform Anatomical Gift Act and state laws to either specify that when the decedent has authorized transplantation, this denotes authorization for research followed by transplantation, or to add the option to participate in organ donor intervention research to the list of choices for the donor.
There are no requirements currently for what information about donation options, including research, should be provided to individuals who are contemplating registering to be an organ donor, the report says. To improve transparency and public trust in the organ donation process involving research prior to transplantation, the OPTN, OPOs, Health Resources and Services Administration, advocacy organizations, and relevant professional associations should develop and test communication strategies and materials that explain organ donor intervention research and disseminate those resources -- such as template language for donor registries -- once effective messaging is identified.
When a post-mortem research intervention is administered prior to organ recovery and the intent is to have an effect on a specific organ -- the target organ -- the intervention could affect other organs from the same donor that may also be removed and transplanted after the intervention -- non-target organs. As a result, many transplant recipients across multiple transplant centers could become human subjects in a single organ donor intervention research study.
The committee proposed a two-stage process for obtaining consent from transplant candidates who could receive a target or non-target research organ. In the first stage, which would be part of the clinical consent process that begins at the time of patient intake and continues through wait-listing, information on organ donor intervention research is provided and the transplant candidate is asked to decide whether they would consider receiving a research organ. The second stage would occur when an organ is being offered to the transplant candidate, following research informed-consent processes as determined by the single institutional review board for organ donor intervention research.
A major reason for the lag in organ donor intervention research, the committee found, is the lack of central oversight necessary to overcome the complexities of this geographically and clinically dispersed research. Therefore, the report recommends the establishment of centralized management and oversight of organ donor intervention research in order to ensure equitable, transparent, and high-quality research.
The report also includes recommendations for creating electronic tools to ensure that organ donor intervention studies are listed on a publicly available website and for tracking and monitoring research outcomes.
The study was sponsored by American Association for the Study of Liver Diseases; American Society of Transplant Surgeons; American Society of Transplantation; Association of Organ Procurement Organizations; Gift of Life Donor Program; Health Resources and Services Administration; Laura and John Arnold Foundation; National Heart, Lung, and Blood Institute; National Institute of Allergy and Infectious Diseases; National Institute of Diabetes and Digestive and Kidney Diseases; National Kidney Foundation; OneLegacy Foundation; and the Transplantation Society. The National Academies of Sciences, Engineering, and Medicine are private, nonprofit institutions that provide independent, objective analysis and advice to the nation to solve complex problems and inform public policy decisions related to science, technology, and medicine. The National Academies operate under an 1863 congressional charter to the National Academy of Sciences, signed by President Lincoln. For more information, visit http://national-academies.
Download the report at http://www.
Members of the committee that conducted the study and wrote the report will present their findings and recommendations and answer questions during a public webinar beginning at 2 p.m. EDT on Thursday, Oct. 19. Please register for the webinar here.
Dana Korsen, Media Relations Officer
Andrew Robinson, Media Relations Assistant
Office of News and Public Information
202-334-2138; e-mail email@example.com
Copies of Opportunities for Organ Donor Intervention Research: Saving Lives by Increasing the Quality and Quantity of Organs for Transplantation are available from the National Academies Press on the Internet at http://www.
THE NATIONAL ACADEMIES OF SCIENCES, ENGINEERING, AND MEDICINE
Health and Medicine Division
Board on Health Sciences Policy
Committee on Issues in Organ Donor Intervention Research
James F. Childress* (chair)
John Allen Hollingsworth Professor of Ethics Emeritus
University of Virginia
Diana L Clark
President and Chief Executive Officer (retired)
I. Glenn Cohen
Professor of Law, and
Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics
Harvard Law School
Michele Bratcher Goodwin
Chancellor's Professor of Law, and
Director, Center for Biotechnology and Global Health Policy
School of Law
University of California
Biomedical Ethics, Experimental Medicine,
Social Studies in Medicine
Robert B. McMillen Chair and Chief, Organ Transplantation and the Laboratory for Transplantation Biology (retired)
Swedish Medical Center
Chairman and Chief Executive Officer
First Samurai Consulting LLC
Great Falls, Va.
Glenn F. Pierce
Chief Medical Officer, Hematology (retired)
La Jolla, Calif.
Lainie Friedman Ross
Carolyn and Matthew Bucksbaum Professor of Clinical Medical Ethics, and
Associate Director, MacLean Center for Clinical Medical Ethics
University of Chicago
Frances Glessner Lee Professor of Medical Ethics, Anesthesia, and Pediatrics, and
Director, Center for Bioethics
Harvard Medical School
Madge and Dennis T. McLawhorn University Professor of Business, Public Policy, and Medicine
James B. Young
Executive Dean and Professor of Medicine
Cleveland Clinic Lerner College of Medicine
Case Western Reserve University
Cathy T. Liverman
*Member, National Academy of Medicine